| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
118,506,000 |
| Market
Cap: |
432.55(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.65 - $8.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.7 |
| Insider 3/6 Months : 8.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
44,630 |
44,630 |
471,648 |
| Total Buy Value |
$0 |
$166,024 |
$166,024 |
$2,724,191 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
6 |
| Total Shares Sold |
2,447 |
54,627 |
96,836 |
590,364 |
| Total Sell Value |
$19,013 |
$243,259 |
$380,390 |
$5,527,958 |
| Total People Sold |
1 |
4 |
6 |
14 |
| Total Sell Transactions |
1 |
8 |
14 |
36 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nashat Amir |
Director |
– • – |
2018-12-19 |
4 |
S |
$13.17 |
$1,222,592 |
I/I |
(91,210) |
1,856,660 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2018-12-13 |
4 |
S |
$16.67 |
$296,563 |
I/I |
(17,788) |
1,947,870 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2018-12-12 |
4 |
S |
$16.78 |
$7,132,690 |
I/I |
(425,000) |
1,965,658 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2018-12-11 |
4 |
S |
$16.71 |
$1,379,183 |
I/I |
(82,528) |
2,390,658 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2018-09-25 |
4 |
B |
$13.50 |
$50,000,004 |
I/I |
3,703,704 |
10,359,666 |
2.25 |
- |
|
| Abbot Stewart |
Chief Development Officer |
• – – |
2018-05-15 |
4 |
OE |
$4.89 |
$139,411 |
D/D |
21,054 |
64,917 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2017-10-16 |
4 |
S |
$4.07 |
$3,256 |
D/D |
(800) |
124,881 |
|
- |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2017-10-16 |
4 |
S |
$4.08 |
$2,856 |
D/D |
(700) |
90,591 |
|
- |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2017-10-16 |
4 |
S |
$4.10 |
$2,050 |
D/D |
(500) |
45,418 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2017-10-13 |
4 |
S |
$3.87 |
$63,344 |
D/D |
(16,368) |
125,681 |
|
- |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2017-10-13 |
4 |
S |
$3.86 |
$48,347 |
D/D |
(12,525) |
91,291 |
|
- |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2017-10-13 |
4 |
S |
$3.83 |
$29,074 |
D/D |
(7,591) |
45,918 |
|
- |
|
| Rastetter William H |
Director |
– • – |
2016-11-23 |
4 |
B |
$2.66 |
$999,998 |
I/I |
375,939 |
459,272 |
2.1 |
- |
|
| Storgard Chris |
Chief Medical Officer |
• – – |
2016-11-23 |
4 |
B |
$2.66 |
$99,997 |
I/I |
37,593 |
37,593 |
1.99 |
- |
|
| Coughlin Timothy P |
Director |
– • – |
2016-11-23 |
4 |
B |
$2.66 |
$149,997 |
D/D |
56,390 |
56,390 |
2.39 |
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2016-08-23 |
4 |
OE |
$1.37 |
$3,521 |
D/D |
2,570 |
142,049 |
|
- |
|
| Storgard Chris |
Chief Medical Officer |
• – – |
2016-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
9,090 |
9,090 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2016-01-18 |
4 |
OE |
$1.37 |
$11,238 |
D/D |
7,500 |
139,479 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2016-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
10,956 |
131,979 |
|
- |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,388 |
103,816 |
|
- |
|
| Abbot Stewart |
Chief Development Officer |
• – – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,863 |
43,863 |
|
- |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,633 |
53,509 |
|
- |
|
| Fate Therapeutics Inc |
Chief Scientific Officer |
• – – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,388 |
103,816 |
|
- |
|
| Fate Therapeutics Inc |
General Counsel and Secretary |
• – – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,633 |
53,509 |
|
- |
|
| Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2016-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,863 |
43,863 |
|
- |
|
335 Records found
|
|
Page 11 of 14 |
|
|
0.05 (1.35%) 
